04:35 PM EDT, 08/07/2025 (MT Newswires) -- Reshma Kewalramani, Director, CEO & President, on August 06, 2025, executed a purchase for 10,000 shares in Vertex Pharmaceuticals ( VRTX ) for $3,895,768. Following the Form 4 filing with the SEC, Kewalramani has control over a total of 115,968 common shares of the company, with 115,968 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/875320/000087532025000220/xslF345X05/wk-form4_1754598207.xml